Dell Technologies has joined forces with the University of Limerick's Digital Cancer Research Centre to develop an artificial intelligence platform for cancer treatment.
The technology is designed to help clinicians provide more effective cancer care for patients with B-cell lymphoma.
The AI platform, which was created by Dell for UL, delivers high performance computing power to accelerate oncology and precision medicine research.
It produces cancer patient digital twins for better diagnostics.
A digital twin is a virtual model designed to accurately reflect a physical object.
Dell said that with the new AI platform, researchers can rapidly accelerate biomarker testing for cancer, gain a better understanding of how to treat patients with B-cell lymphoma and develop personalised therapies based on a person’s tumour characteristics.
"Through our partnership with the Dell Technologies team, we will be able to advance our knowledge of how cells go wrong during cancer development and find new ways to diagnose and treat cancer patients," said Paul Murray, Professor of Molecular Pathology at University of Limerick and Director of the Digital Pathology Unit at the Digital Cancer Research Centre.
Catherine Doyle, Managing Director of Dell Technologies Ireland, said the new AI platform will ultimately help researchers and healthcare professionals deliver precision treatments for patients with B-cell lymphoma by understanding how it develops.
"Through the creation of these digital twins, the University of Limerick and Dell are taking clinical research to a new level," Ms Doyle said.
"Together, we are harnessing the power of data through new technologies to benefit patients and healthcare professionals globally," she added.
